Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study
Read in context, it is a secondary, exploratory outcome from a Phase 2 trial whose primary endpoint, change in cerebral glucose metabolism, was negative, and whose cognitive signal was modest
Check out pharma's other fastest growing drugs here: To view or add a comment, sign in - Download PDF Brochure: GLP-1 analogue therapies are transforming metabolic disease management from type 2 diabetes to obesity and cardiometabolic risk reduction
MJ: Data curation, Investigation, Software, Writing original draft
Very pleased with all products Ive purchased from VitaStir very quick service